REGENXBIO (RGNX) said Thursday it intends to offer and sell $100 million of its common stock in an underwritten public offering, subject to market and other conditions.

The company said it also plans to grant the underwriters a 30-day option to purchase up to an additional 15% of the common shares sold in the offering.